Corcept Therapeutics (CORT) vs Viatris (VTRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Viatris (VTRS) has outperformed Corcept Therapeutics (CORT) over the past year, gaining 74.9% versus a gain of 34.0%. Over five years, CORT leads with a +491.5% price change compared with +29.6% for VTRS. Viatris is the larger company by market cap ($20.13 billion vs $13.01 billion), about 1.5 times the size, while Corcept Therapeutics is growing revenue faster (+12.8% vs -3.0%).
On valuation, Viatris trades at a lower forward P/E (6.6x vs 27.3x for Corcept Therapeutics). Viatris pays a dividend yielding 2.74%, while Corcept Therapeutics does not currently pay one. Corcept Therapeutics converts more of its revenue into profit, with a net margin of 13.1% versus -24.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CORT | VTRS |
|---|---|---|
| Share price | $120.33 | $17.53 |
| Market cap | $13.01B | $20.13B |
| 1-day change | +1.51% | +0.49% |
| YTD return | +240.63% | +40.08% |
| 1-year return | +34.05% | +74.92% |
| 5-year return | +491.52% | +29.57% |
| P/E ratio (TTM) | 267.40 | — |
| Forward P/E | 27.33 | 6.55 |
| EPS (TTM) | $0.45 | $-0.36 |
| Dividend yield | 0.00% | 2.74% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | $761.41M | $14.30B |
| Revenue growth (YoY) | +12.79% | -2.98% |
| Net income (latest FY) | $99.65M | $-3.51B |
| Gross margin | 98.30% | 35.06% |
| Operating margin | 5.88% | -18.62% |
| Net margin | 13.09% | -24.58% |
| 52-week high | $126.38 | $18.43 |
| 52-week low | $28.66 | $9.69 |
| Distance from 52-week high | -4.79% | -4.91% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +17.18% | +12.41% |
| Average volume | 1.29M | 9.25M |
| Shares outstanding | 108.10M | 1.15B |
| Employees | 730 | 30,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTRS has outperformed CORT by 40.9 percentage points over the past year.
- Viatris offers a meaningfully higher dividend yield (2.74% vs 0.00%).
- Corcept Therapeutics is more profitable, keeping 13.1 cents of every revenue dollar as net income versus -24.6 cents for Viatris.
- Corcept Therapeutics grew revenue faster in its latest fiscal year (+12.79% vs -2.98%).
About Corcept Therapeutics
CORT stock →Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Health Care · Biotechnology: Pharmaceutical Preparations · 730 employees
About Viatris
VTRS stock →Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 30,000 employees
CORT vs VTRS FAQ
Which is bigger, Corcept Therapeutics or Viatris?
Viatris (VTRS) is larger, with a market capitalization of $20.13B compared with $13.01B for Corcept Therapeutics (CORT).
Which stock has performed better over the past year, CORT or VTRS?
VTRS returned +74.92% over the past 12 months, compared with +34.05% for CORT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Corcept Therapeutics or Viatris?
Viatris pays a dividend yielding 2.74%, while Corcept Therapeutics does not currently pay a regular dividend.
Are Corcept Therapeutics and Viatris in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.